Our senior consultants provide technical and strategic leadership to our teams and projects

Ann-Marie Chapman

Head of Insight

Ann-Marie joined BresMed in 2014 and has over 18 years of experience in HEOR across the consultancy, pharmaceutical and medical technology industries.

Ann-Marie has a breadth of experience in supporting HTA submissions, new product implementation and stakeholder engagement with appropriate value messages.

Catherine Rycroft

Principal Research Associate

Catherine joined BresMed in 2014 and has over 10 years of consultancy experience in market access, HEOR and medical communications.

She has a background in biological research, a PhD in Microbiology from the University of Reading, and she spent 4 years working in molecular biology research for a biotech start-up.

Catherine has a strong publication record and extensive experience in medical writing; preparing a range of market access deliverables, including global value dossiers, HTA dossiers and systematic, structured and targeted literature reviews; and developing communication pieces such as manuscripts, slide sets, abstracts, posters and newsletters.

Chrissy Almond

UK Head of Health Economics

Chrissy joined BresMed in 2010 with a background in mathematics. She has experience in leading health economic modelling and HTA submissions to NICE, the SMC, the NCPE and the TLV, as well as developing and leading projects involving early economic models and global economic models.

Chrissy has expertise in the field of ophthalmology, having led projects across a wide range of ophthalmological indications.

Daniel Gladwell

Principal Consultant

Dan joined BresMed in 2011. Prior to this he worked for Takeda Europe R&D, leading the pre-, peri- and post-launch HEOR planning for diabetes and obesity compounds. Dan has led the development of cost-effectiveness models and HTA submissions – providing strategic guidance on HEOR and market access.

While working at BresMed, Dan has been undertaking a PhD at the University of Sheffield, investigating the dynamic impact of health difficulties in adolescence on the formation of valued abilities and skills.

Dawn Lee

Head of Health Economics Analysis

Dawn joined BresMed in 2010, she has over 10 years of experience in economic consultancy and modelling, and now leads the Health Economics Analysis team.

She has a mathematical and technical background and a core skill set covering model development and design, complex simulation and sequencing models, statistical analysis, quality control and manufacturer representation for HTA. She has extensive experience in the development of economic models and modelling for HTA submissions in a wide variety of countries, including England, Wales, Scotland, Ireland, Sweden, Norway, the Czech Republic, Hungary, Spain, Italy, Belgium, Greece, Switzerland, France, Germany, Brazil, Mexico, South Korea and Israel.

Elaine Tate

Head of Commercial &
Country Head, BresMed America
 

Elaine joined BresMed in 2012 and has vast experience covering the entire pharmaceutical R&D process. During her career of over 25 years, she has worked at Wellcome Research Laboratories, subsidiaries of Serono and Novartis, R&D software companies and in contract research and consultancy.

Elaine supports the BresMed board in the areas of business development, business planning, contracting and compliance.

Elizabeth Thurgar

Principal Health Economist

Elizabeth joined BresMed in 2016 and has worked as a health economist for over 8 years. She has also worked as a management consultant (health-focus) and a government economist (Civil Service Fast Stream).

Elizabeth has experience working with pharmaceutical firms to develop HTA submissions to NICE and the SMC. She also has experience in designing and building budget impact models and value proposition tools. Most recently she worked as a member of a Technology Assessment Group for NICE, critiquing manufacturer submissions for single technology appraisals and multiple technology appraisals.

Kunal Srivastava

Head of Systematic Review &
Country Manager, BresMed India

Kunal joined BresMed in 2014 and has over 10 years of experience in HEOR consulting for the pharmaceutical industry. He has a background in pharmaceutical sciences and extensive experience in systematic reviews, literature reviews, meta-analyses, indirect comparisons and HTA submissions.

Kunal has established, trained and leads a team of systematic reviewers, providing strategic support working on both HTA and non-HTA reviews. He is also responsible for running the BresMed India office in Gurugram.

Lisa Cox

Head of HTA &
Head of Consulting & Management

Lisa joined BresMed in 2012 and has over 9 years of consultancy experience in healthcare communications and outcomes research, and over 10 years of project management experience. She has worked on over 50 submissions to UK HTA agencies.

Lisa takes a lead role on complex HTA projects, utilising her experience in the industry, a clinical background and her project management skills to manage and deliver multifaceted projects to define project strategy and direction and to meet client objectives. Lisa also trains, supports and leads a team of project leads and project managers.

Marjolijn van Keep

Senior Health Economist &
Country Head, BresMed Netherlands

Marjolijn joined BresMed in 2013 having completed a BSc and MSc in Pharmacy and a post-graduate certificate in International Health Technology Assessment.

Marjolijn is a senior member of the health economic analysis team. She has developed several global cost-effectiveness models, and has worked on submissions to HTA agencies such as NICE, the SMC, the AWMSG, the NCPE and Zorginstituut Nederland.

Neil Roskell

Head of Statistics

Neil joined BresMed in 2014 and has over 20 years of experience (8 years at GSK and 12 years in consultancy) in health outcomes statistics, clinical trial statistics and epidemiology.

Neil has contributed to, and taken responsibility for, statistical input to submissions to many international regulatory agencies and HTA agencies, including those in the US, UK, Canada, Germany and Australia.

Nic Brereton

Chief Executive Officer

Nic is the founder of BresMed, which, since 2006, he has grown from a small Sheffield-based consultancy to a highly respected international company with over 100 staff across six countries.

Nic has worked in consulting with pharmaceutical companies for over 15 years. In addition to running this successful and growing HEOR consultancy, he regularly attends and chairs clinical and health economic advisory boards.

Richard Birnie

Principal Statistician

Richard joined BresMed in 2017 from Kleijnen Systematic Reviews Ltd and has over 4 years’ experience in systematic reviews and network meta-analysis. Richard also brings a strong understanding of fundamental biological principles in oncology and experience across a range of disease areas including ophthalmology and multiple sclerosis. Richard has been responsible for the statistical input to HTA submissions, including survival and utility analysis. He has also worked as part of an ERG on behalf of NICE reviewing UK HTA submissions.

Prior to moving into the field of HTA, Richard worked as a research scientist, he has a PhD in molecular biology and has studied a wide range of different cancers including prostate, colorectal and medulloblastoma.

Ron Akehurst

Chairman

Ron is Professor Emeritus in Health Economics at the University of Sheffield and a visiting Professor at Eotvos Laurent and Corvinus Universities in Budapest. He was founding Dean of ScHARR at the University of Sheffield (1993–2010), and worked for 40 years as an academic, during which time he was involved in many methodological developments in HTA. He was a founding member of the NICE Appraisal Committee and served on the NICE Topic Selection Committee, the NICE Public Health Interventions Advisory Committee and the NICE Diagnostics Advisory Committee. He formerly served as an Economic Advisor at the Department of Health, as a Specialist Advisor to the House of Commons Health Select Committee and as a Non-Executive Board Member of Rotherham Health Authority.

Ron moved from academia to BresMed in 2011. Currently, he is a member of the NICE Highly Specialised Technologies Committee and the Rare Diseases Advisory Group at NHS England.

Sallie Stradwick

Head of Clinical Evidence Review

Sallie has been instrumental in developing the Clinical Evidence Review team since joining BresMed in its infancy in 2010.

She has worked in clinical research for 15 years, specifically reviewing clinical evidence within a HEOR context for the last 6 years, developing value messages and offering strategic support in demonstrating clinical benefit as part of dossier development (value and reimbursement) and primary research projects (systematic reviews, meta-analyses, targeted literature reviews and gap analyses).

Sandy Kildegaard Nielsen

Principal Consultant &
Regional Manager, BresMed Scandinavia

Sandy joined BresMed in 2014 with over 15 years of experience in the pharmaceutical industry. He was responsible for strategic input on HEOR, pricing and market access. He has led several launches of new products and line extensions, developing and implementing value propositions, HEOR tools, pricing, market access strategies and HTA submissions in Europe, Latin America and Asia.

Sandy set up the BresMed India office and is now based in Denmark to build BresMed’s Scandinavian business.

Sinéad Mahon

Senior Consultant &
Country Head, BresMed Ireland

Sinéad joined BresMed in 2016 and has over 6 years of experience in HEOR, strategic market access; pricing strategy, including price negotiations and patient access scheme development, and project management.

Sinéad has worked with pharmaceutical firms in Ireland on multiple HTA submissions to the NCPE, and has experience in designing and building budget impact models and value proposition tools.

Sinéad takes a lead role on complex BresMed projects, utilising her industry experience, economic background and project management skills to manage and deliver multifaceted projects to meet client objectives.

Steve Beard

Chief Business Development Officer

Steve joined BresMed in 2013 and has over 20 years of HTA and HEOR experience in a senior consulting and managerial role, developing and leading teams providing strategic and health economics guidance and submission advice within the pharmaceutical and medical devices industry.

He has extensive experience in the areas of health economic modelling, statistical analysis, HTA strategy and market access value demonstration. Steve is an honorary Senior Research Fellow, Health Economics & Decision Science (HEDS), ScHARR, University of Sheffield.

Yang Meng

Principal Health Economist

Yang joined BresMed in 2014 and has over 10 years of health modelling and HTA experience spanning PhD research in infectious disease modelling, academia at ScHARR at the University of Sheffield, and HEOR consultancy at BresMed.

He has taken responsibility for, and contributed to, modelling and statistical analysis for successful submissions to many international regulatory and HTA agencies in countries including England, Wales, Scotland, Ireland, Spain, Italy, the Czech Republic, Slovakia, Bulgaria and Canada.

Zoe Philips

Chief Operating Officer

Zoe joined BresMed in 2015 and has over 18 years of experience from a career spanning academia, industry, and HEOR and market access consultancy. She has a background in decision modelling and health economics.

Zoe has extensive experience in the areas of HTA, payer and reimbursement strategy, HEOR evidence implementation and in communicating health economics and value messages.